The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and ...

Zanubrutinib shows safety and efficacy in CLL/SLL patients, regardless of prior ibrutinib treatment, with lower treatment-limiting and cardiac adverse events compared to ibrutinib. The study included ...

When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...